Icli, F. Et Al. 2011. Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.. JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15 .

Icli, F., Altundag, K., Coskun, U., Paydas, S., BAŞARAN, G., SAİP, P. M., ... Dogu, G. G.(2011). Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.. JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15.

Icli, F. Et Al. "Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.," JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15, 2011

Icli, F. Et Al. "Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.." JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15, 2011

Icli, F. Et Al. (2011) . "Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.." JOURNAL OF CLINICAL ONCOLOGY , vol.29, no.15.

@article{article, author={F. Icli Et Al. }, title={Nine versus 52 weeks of adjuvant trastuzumab in early breast cancer: An observational study of the Turkish Oncology Group.}, journal={JOURNAL OF CLINICAL ONCOLOGY}, year=2011}